Contradicted and initially stronger effects in highly cited clinical research. JAMA
2005; 294: 218–28.
Pereira, TV, Horwitz, RI, Ioannidis, JP.
Empirical evaluation of very large treatment effects of medical interventions. JAMA
2012; 308: 1676–84.
Nieminen, P, Rucker, G, Miettunen, J, Carpenter, J, Schumacher, M.
Statistically significant papers in psychiatry were cited more often than others. J Clin Epidemiol
2007; 60: 939–46.
Hunt, GE, Cleary, M, Walter, G.
Psychiatry and the Hirsch h-index: the relationship between journal impact factors and accrued citations. Harv Rev Psychiatry
2010; 18: 207–19.
Trikalinos, TA, Churchill, R, Ferri, M, Leucht, S, Tuunainen, A, Wahlbeck, K, et al.
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol
2004; 57: 1124–30.
A rating scale for depression. J Neurol Neurosurg Psychiatry
1960; 23: 56–62.
Kay, SR, Fiszbein, A, Opler, LA.
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Why most published research findings are false. PLoS Med
2005; 2: e124.
Ho, PM, Peterson, PN, Masoudi, FA.
Evaluating the evidence: is there a rigid hierarchy? Circulation
2008; 118: 1675–84.
A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med
2000; 19: 3127–31.
Statistical Power Analysis in the Behavioral Sciences. Erlbaum, 1988.
Higgins, J, Green, S.
Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Cochrane Collaboration, 2011.
In t’ Veld, BA, Ruitenberg, A, Hofman, A, Launer, LJ, van Duijn, CM, Stijnen, T, et al.
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med
2001; 345: 1515–21.
Breitner, JC, Baker, LD, Montine, TJ, Meinert, CL, Lyketsos, CG, Ashe, KH, et al.
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement
2011; 7: 402–11.
Street, JS, Clark, WS, Gannon, KS, Cummings, JL, Bymaster, FP, Tamura, RN, et al.
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry
2000; 57: 968–76.
De Deyn, PP, Carrasco, MM, Deberdt, W, Jeandel, C, Hay, DP, Feldman, PD, et al.
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry
2004; 19: 115–26.
Tohen, M, Jacobs, TG, Grundy, SL, McElroy, SL, Banov, MC, Janicak, PG, et al.
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry
2000; 57: 841–9.
McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J.
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord
2009; 11: 673–86.
Marshall, M, Lockwood, A, Bradley, C, Adams, C, Joy, C, Fenton, M.
Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry
2000; 176: 249–52.
Wood, L, Egger, M, Gluud, LL, Schulz, KF, Juni, P, Altman, DG, et al.
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ
2008; 336: 601–5.
Savovic, J, Jones, HE, Altman, DG, Harris, RJ, Juni, P, Pildal, J, et al.
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med
2012; 157: 429–38.
Replication and p intervals: p values predict the future only vaguely, but confidence intervals do much better. Perspect Psychol Sci
2008; 3: 286–300.
Why most discovered true associations are inflated. Epidemiology
2008; 19: 640–8.
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM.
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry
2012; 200: 97–106.
Schulz, KF, Chalmers, I, Hayes, RJ, Altman, DG.
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA
1995; 273: 408–12.